Related Experiment Video
Updated: Mar 16, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
Antipsychotic drugs in Huntington's disease
E Unti1, S Mazzucchi1, G Palermo1
1a Department of Clinical and Experimental Medicine-Neurology Unit , University of Pisa , Pisa , Italy.
Insights
This review examines neuroleptics for Huntington
Area of Science:
- Pharmacology and Neurology
- Neurodegenerative Diseases
Background:
- Huntington's disease (HD) presents complex motor and psychiatric symptoms.
- Effective pharmacological management for HD symptoms remains a clinical challenge.
- Limited randomized controlled trials (RCTs) exist for neuroleptic use in HD.
Purpose of the Study:
- To review the pharmacological characteristics of neuroleptics used in treating Huntington's disease.
- To evaluate current treatment guidelines and identify unmet clinical needs in HD management.
Main Methods:
- Systematic literature search of PubMed using terms 'Huntington's disease', 'Antipsychotic drugs', 'Neuroleptic drugs', and specific drug names.
- Evaluation of existing clinical guidelines and identification of unmet needs in HD treatment.
Main Results:
- Antipsychotics are frequently used as a first-line treatment for chorea in HD, especially with psychiatric symptoms or when tetrabenazine poses risks.
- Second-generation antipsychotics are preferred to minimize extrapyramidal side effects but may increase metabolic risks.
- Current evidence relies heavily on case reports, with a scarcity of RCTs and drug comparison studies.
Conclusions:
- Antipsychotics are a valid strategy for managing HD symptoms, with second-generation agents offering a potentially better side-effect profile.
- The development of 'dopamine stabilizers' like pridopidine may offer future alternatives by modulating dopamine transmission.
- Further high-quality research, including RCTs, is needed to establish optimal neuroleptic use in Huntington's disease.
Introduction:
The aim of this review is to overview the pharmacological features of neuroleptics experienced in the treatment of Huntington's disease (HD) symptoms. Despite a large number of case reports, randomized controlled trials (RCT) and drug comparison studies are lacking. Areas covered: After evaluating current guidelines and clinical unmet needs we searched PubMed for the term 'Huntington's disease' cross referenced with the terms 'Antipsychotic drugs' 'Neuroleptic drugs' and single drug specific names. Expert commentary: In clinical practice antipsychotics represent the first choice in the management of chorea in the presence of psychiatric symptoms, when poor compliance is suspected or when there is an increased risk of adverse events due to tetrabenazine. Antipsychotics are considered valid strategies, with the second generation preferred to reduce extrapyramidal adverse events, however they may cause more metabolic side effects. In the future 'dopamine stabilizers', such as pridopidine, could replace antipsychotics modulating dopamine transmission.
Related Concept Videos
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Psychosis and Antipsychotic Drugs: Overview
Antipsychotic Drugs: Typical and Atypical Agents
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications

